Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Blast Crisis 1

Interventions

Cytarabine 197Azacitidine 143Cyclophosphamide 136fludarabine phosphate 112fludarabine 97Busulfan 96venetoclax 95Mycophenolic Acid 82Whole-Body Irradiation 81Tacrolimus 78Peripheral Blood Stem Cell Transplantation 78Decitabine 62Filgrastim 56Granulocyte Colony-Stimulating Factor 54Cyclosporine 53Melphalan 52Methotrexate 51Idarubicin 51Daunorubicin 49Antilymphocyte Serum 47Clofarabine 43Etoposide 41Thiotepa 35Gemtuzumab 34Mitoxantrone 32Stem Cell Transplantation 31CPX-351 27Specimen Handling 25Radiotherapy 25thymoglobulin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Myeloid, Acute × troxacitabine × Clear all
NCT00129948 2006-11-03

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

SGX Pharmaceuticals, Inc.

Phase 2 Terminated
211 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡